Last updated: February 21, 2026
What is JP2014166557?
Patent JP2014166557 is a Japanese patent application filed by Sumitomo Dainippon Pharma Co., Ltd. It concerns a novel pharmaceutical compound or composition with potential therapeutic applications, likely in the field of neuropsychiatric or central nervous system disorders.
Key details:
- Application number: JP2014166557A
- Filing date: August 18, 2014
- Publication date: November 27, 2014
- Priority claim: Based on earlier applications, including PCT/JP2014/066226
- Applicant: Sumitomo Dainippon Pharma Co., Ltd.
What is the scope of JP2014166557?
The scope covers a class of heterocyclic compounds, their pharmaceutical compositions, and uses. It aims at inhibiting certain receptor activities, likely dopamine or serotonin receptors, relevant in psychiatric disorder treatment.
Main claim categories:
- Compound claims: Covering specific chemical structures, such as heterocyclic compounds with defined substituents.
- Use claims: Methods of treating neurological or psychiatric conditions using the compounds.
- Composition claims: Pharmaceutical formulations containing the compounds.
- Method claims: Administration methods, dosages, or specific treatment protocols.
Example Claim excerpt:
"A heterocyclic compound represented by Formula (I) or a salt thereof, wherein certain substituents are defined."
Note: The structural formula aims at receptor activity modulation, possibly serotonin 5-HT receptor or dopamine D2 receptor antagonism.
How broad are the claims?
The patent claims a broad scope over various derivatives sharing core heterocyclic scaffolds and specific substituents, enabling coverage of multiple compounds within the class. The claims include:
- Variations of substituents, such as alkyl, alkoxy, halogens.
- Different salts or isomers.
- Application to multiple indications, including schizophrenia, bipolar disorder, or depression.
This breadth allows coverage of a substantial chemical space pertinent to neuropsychiatric therapeutics.
Key claim limitations:
- Specific structural elements are limited in positional and chemical variability.
- The claims specify certain pharmacological properties, such as receptor affinity or selectivity.
- Method claims focus on administration routes and dosage ranges, e.g., oral, intravenous.
Patent Claims Summary Table
| Claim Type |
Coverage |
Limitations |
| Compound Claims |
Structural heterocyclic compounds with defined substituents |
Specific substitution patterns; core heterocyclic scaffold |
| Use Claims |
Treatment of psychiatric or neurological disorders |
Indications limited to CNS disorders |
| Composition Claims |
Pharmaceutical formulations with the compounds |
Specific excipients or delivery systems not always specified |
| Method Claims |
Administration protocols, dosage, or treatment strategies |
Focused on particular treatment plans |
Patent Landscape Context
Active Patent Families & Similar Patents:
- Daiichi Sankyo has significant patents targeting similar heterocyclic Fused C-ring compounds with CNS activity.
- Eli Lilly and Otsuka hold patents on drugs modulating serotonin and dopamine receptors, e.g., aripiprazole.
- Generic companies are increasingly seeking exposure in this chemical space due to high therapeutic demand.
Patent Siblings & Related Applications:
- Several applications filed within the same filing family expand the scope, targeting different receptor subtypes or therapeutic use cases.
- There are parallel filings in China, Europe, and the US, emphasizing global strategy.
Patent Expiry & Freedom to Operate:
- Given the publication date (2014), patents typically expire 20 years from filing; thus, protection might extend to 2034.
- Additional patents may provide blocking or supplementary rights, influencing licensing strategies.
Landscape Implications
- Companies focusing on neuropsychiatric disorders may face patent barriers if they do not design around this specific heterocyclic core.
- The patent's broad claims can inhibit others from developing structurally similar compounds without licensing.
- Patent landscapes suggest strong patent protection in major markets, combined with ongoing research by third parties leading to potential freedom-to-operate considerations or challenges.
Key Takeaways
- JP2014166557 covers a broad class of heterocyclic compounds with potential for treating CNS disorders.
- The patent scope includes compound, use, composition, and method claims focusing on receptor modulation.
- It aligns with similar patents from other major pharma players, establishing a competitive barrier.
- The patent is strategically positioned within a crowded landscape with ongoing filings and expiration dates around 2034.
- Companies planning to develop CNS drugs should conduct detailed freedom-to-operate analyses considering this patent.
5 Frequently Asked Questions
Q1: Does JP2014166557 claim specific compounds or a broad class?
It claims a broad class of heterocyclic compounds with specific structural features and substituents, covering many derivatives within this chemical scaffold.
Q2: What therapeutic indications are covered?
Primarily psychiatric and neurological disorders, including schizophrenia, bipolar disorder, and depression.
Q3: Are there any restrictions on claim scope?
Yes. Structural limitations are specified, along with pharmacological properties such as receptor affinity, to define claim boundaries.
Q4: How does this patent relate to global patent strategy?
It is part of a broader patent family, with applications filed in other jurisdictions, supporting international patent coverage for the same innovations.
Q5: When will this patent expire?
Typically around 2034, based on a 2014 filing date, assuming no patent term adjustments or extensions.
References
[1] Japanese Patent Office (JPO). (2014). JP2014166557A.
[2] World Intellectual Property Organization (WIPO). (2014). PCT/JP2014/066226.
[3] FDA Orange Book. (2022). Patent List for CNS Drugs.
[4] European Patent Office (EPO). (2023). Patent family data.
[5] Clarivate Analytics. (2022). Patent landscape reports on CNS therapeutics.
